The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer

Rexin, Peter; Tauchert, Alessa; Hänze, Jörg; Heers, Hendrik; Schmidt, Ansgar; Hofmann, Rainer; Hegele, Axel

doi:10.21873/anticanres.12517

Cited by 9 publications

(8 citation statements)

References 30 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It recognizes CD200 as its ligand, which is expressed on various normal tissues such as the central nervous system, retina, hair follicular cells, vascular endothelial cells, and thymocytes, as well as activated T, B, and DCs, in addition to its expression on various tumors (265). CD200 is considered as a marker of tumor progression since it is overexpressed on various cancers of both hematopoietic and non-hematopoietic origin, such as acute myeloid leukemia, multiple myeloma, hairy cell leukemias, B cell chronic leukemias, melanoma, and ovarian, rectal cancer, and bladder cancer, and its expression is associated with the worst prognosis (266)(267)(268)(269)(270)(271)(272)(273)(274). Moreover, CD200 expression can also be induced on cancer cells (275,276).…”

Section: Cd200rmentioning

confidence: 99%

NK Cell-Based Immune Checkpoint Inhibition

Arooj²,

2020

View full text Add to dashboard Cite

Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an important mode of treatment for cancer patients. The inhibition of immune checkpoints, which are the source of immune escape for various cancers, is one such immunotherapeutic dimension. It has mainly been aimed at T cells in the past, but NK cells are a newly emerging target. Simultaneously, the number of checkpoints identified has been increasing in recent times. In addition to the classical NK cell receptors KIRs, LIRs, and NKG2A, several other immune checkpoints have also been shown to cause dysfunction of NK cells in various cancers and chronic infections. These checkpoints include the revolutionized CTLA-4, PD-1, and recently identified B7-H3, as well as LAG-3, TIGIT & CD96, TIM-3, and the most recently acknowledged checkpoint-members of the Siglecs family (Siglec-7/9), CD200 and CD47. An interesting dimension of immune checkpoints is their candidacy for dual-checkpoint inhibition, resulting in therapeutic synergism. Furthermore, the combination of immune checkpoint inhibition with other NK cell cytotoxicity restoration strategies could also strengthen its efficacy as an antitumor therapy. Here, we have undertaken a comprehensive review of the literature to date regarding NK cell-based immune checkpoints.

show abstract

Section: Cd200rmentioning

confidence: 99%

NK Cell-Based Immune Checkpoint Inhibition

Arooj²,

2020

View full text Add to dashboard Cite

show abstract

“…High levels of CD200 have been found to be expressed on various types of human cancer cells, including hairy cell leukemia ( 55 ), acute myeloid leukemia ( 56 ), malignant melanoma ( 22 ), CLL ( 21 ), multiple myeloma ( 21 ), testicular cancer ( 21 ), renal carcinoma ( 21 ), colon carcinoma ( 21 ), and GBM ( 57 ). Moreover, CD200 overexpression is correlated with poor prognosis among some of these cancers, suggesting that high levels of CD200 may facilitate tumorigenesis ( 21 , 58 – 60 ). This observation can be explained by CD200’s primarily inhibitory role in the tumor microenvironment (TME) and the mechanisms through which the protein suppresses immune cell function and activation.…”

Section: Cd200 and Cd200rmentioning

confidence: 99%

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade

Choe

Choi

2023

Front. Oncol.

View full text Add to dashboard Cite

Immune checkpoint molecules function to inhibit and regulate immune response pathways to prevent hyperactive immune activity from damaging healthy tissues. In cancer patients, targeting these key molecules may serve as a valuable therapeutic mechanism to bolster immune function and restore the body’s natural defenses against tumors. CD200, an immune checkpoint molecule, is a surface glycoprotein that is widely but not ubiquitously expressed throughout the body. By interacting with its inhibitory receptor CD200R, CD200 suppresses immune cell activity within the tumor microenvironment, creating conditions that foster tumor growth. Targeting the CD200/CD200R pathway, either through the use of monoclonal antibodies or peptide inhibitors, has shown to be effective in boosting anti-tumor immune activity. This review will explore CD200 and the protein’s expression and role within the tumor microenvironment, blood endothelial cells, and lymph nodes. This paper will also discuss the advantages and challenges of current strategies used to target CD200 and briefly summarize relevant preclinical/clinical studies investigating the immunotherapeutic efficacy of CD200/CD200R blockade.

show abstract

“…The absence of the CD200R signaling was shown to inhibit the development of an endogenous tumor irrespective of the expression of CD200 [155]. A clinical trial using the humanized anti-CD200 mab, Samalizumab is on the way to treating metastatic bladder cancer [32].…”

Section: Immunotherapeutic Approaches Against Cancermentioning

confidence: 99%

Current Perspectives in Cancer Immunotherapy

Christofi

Baritaki

Falzone

et al. 2019

Cancers

164

121

View full text Add to dashboard Cite

Different immunotherapeutic approaches have proved to be of significant clinical value to many patients with different types of advanced cancer. However, we need more precise immunotherapies and predictive biomarkers to increase the successful response rates. The advent of next generation sequencing technologies and their applications in immuno-oncology has helped us tremendously towards this aim. We are now moving towards the realization of personalized medicine, thus, significantly increasing our expectations for a more successful management of the disease. Here, we discuss the current immunotherapeutic approaches against cancer, including immune checkpoint blockade with an emphasis on anti-PD-L1 and anti-CTLA-4 monoclonal antibodies. We also analyze a growing list of other co-inhibitory and co-stimulatory markers and emphasize the mechanism of action of the principal pathway for each of these, as well as on drugs that either have been FDA-approved or are under clinical investigation. We further discuss recent advances in other immunotherapies, including cytokine therapy, adoptive cell transfer therapy and therapeutic vaccines. We finally discuss the modulation of gut microbiota composition and response to immunotherapy, as well as how tumor-intrinsic factors and immunological processes influence the mutational and epigenetic landscape of progressing tumors and response to immunotherapy but also how immunotherapeutic intervention influences the landscape of cancer neoepitopes and tumor immunoediting.

show abstract

The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer

Abstract: This is the first report of CD200 expression in patients with TCC. The significant correlation between CD200 expression and tumor grading may suggest CD200 as a potential target and marker for immunotherapeutic approaches.

Cited by 9 publications

References 30 publications

NK Cell-Based Immune Checkpoint Inhibition

NK Cell-Based Immune Checkpoint Inhibition

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade

Current Perspectives in Cancer Immunotherapy

Contact Info

Product

Resources

About